Assessment of DNA damage-repair capacity in systemic lupus erythematosus patients as a potential biomarker of response to cyclophosphamide.
Not Applicable
Recruiting
- Conditions
- upus nephritisLupus nephritisInflammatory and Immune System - Autoimmune diseases
- Registration Number
- ACTRN12620001287921
- Lead Sponsor
- niversity of Auckland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
>18 years of age
Diagnosed with lupus nephritis
Able to give informed consent
Not currently receiving cyclophosphamide or other alkylating agent
Exclusion Criteria
Not able to provide a blood sample
Currently taking cyclophosphamide or other alkylating agent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method